Rare cancers are considered orphan diseases because of their low incidence rates. This classification often leads to challenges in securing funding for research and development of treatments. Pharmaceutical companies may be less incentivized to invest in drug development for rare cancers due to the smaller market size. Consequently, patients with rare cancers may face limited treatment options and less access to clinical trials.
